We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab (BETH)

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00625898
First Posted: February 29, 2008
Last Update Posted: July 8, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Cancer International Research Group (CIRG)
Hoffmann-La Roche
Genentech, Inc.
Information provided by (Responsible Party):
NSABP Foundation Inc
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2014
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)